Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline forCYP2D6genotype and use of ondansetron and tropisetron
Year: 2016
Type: article
Abstract: 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonists are used in the prevention of chemotherapy- induced, radiation-induced and postoperative nausea and vomiting. CYP2D6 polymorphisms can influence the metabolism of some of these drugs (i.e. ondansetron and tropisetron) thereby affecting drug efficacy. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for ondansetron and tropisetron based on CYP2D6 genotype (updates at www.pharmgkb.org).
DOI: 10.1002/cpt.598
Institutions: Mission Health, St. Jude Children's Research Hospital, Stanford University, University of California San Diego, University of Chicago, Cincinnati Children's Hospital Medical Center, Children's Mercy Hospital, University of Missouri–Kansas City, Universidad de Extremadura, University of Cincinnati, Universitätsklinikum Tübingen, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, University of Tübingen
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: bronze
Funders: Cincinnati Children's Hospital Medical Center, Robert Bosch Stiftung, National Institutes of Health, National Human Genome Research Institute, National Institute of General Medical Sciences, National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Clinical Pharmacogenetics Implementation Consortium (CPIC), G2955879720, PharmGKB: pharmacogenomics knowledge for precision medicine, Better Outcomes for Children: Promoting Excellence in Healthcare Genomics to Inform Policy, Pharmacogenetics of Oxycodone, Personalized Care and Persistent Surgical Pain, Center for Clinical and Translational Science and Training, Predoctoral Training Grant in Pharmacology
OpenAlex ID: W2563534429
